Previous 10 | Next 10 |
The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb ® te...
There are a number of reasons why you might be interested in the future sales/revenue growth of a company. For instance, in order to perform a discounted cash flow analysis of a stock, it's one of the essential inputs. Or perhaps, you believe that the higher a company's projected sales growth,...
Merger activity increased last week with four new deals announced and two deals completed. M&A activity continues to pick up pace as we come close to the end of the third quarter. We had been tracking two of the four new deals announced last week in our "Deals in the Works" table before ...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference. Management will deliver a company presentation for the H.C. Wainwright 22 nd annual global investment virtual conference on Monday, September 14 ...
IMVT-1401 is a novel anti-FcRn OmniAb-derived antibody delivered by subcutaneous injection Registration-enabling Phase 3 trial expected to initiate in the first half of 2021 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMV...
KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug A...
Merger activity increased significantly last week with eight new deals announced and one deal terminated. This is the highest number of deals announced in a single week this year but most of these deals were relatively small compared to the multi-billion-dollar deals we saw in the week prior...
Ligand Pharmaceuticals ( LGND ) is a company with an interesting business model, one which I have provided coverage on at various occasions in the past. The last update on the company and the investment thesis dates March 2019 as I concluded that uncertainty prevails. This uncertainty ca...
Ligand reports planned acquisition of Pfenex Ligand Pharmaceuticals Inc. ( LGND ) announced that it has inked a definitive agreement with Pfenex Inc. ( PFNX ) for acquiring the latter. The companies expect the transaction to be closed in the fourth quarter of 2020, subject to required re...
Ligand Pharmaceuticals (NASDAQ: LGND ) has agreed to acquire Pfenex (NYSEMKT: PFNX ) at $12/share, equivalent to $438M in equity value, representing a 57% premium to Pfenex’s last close price of $7.66 on August 10. More news on: Ligand Pharmaceuticals Incorporated, Pfenex Inc....
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...
2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...